Advertisement
UK markets close in 5 hours 50 minutes
  • FTSE 100

    7,824.28
    -52.77 (-0.67%)
     
  • FTSE 250

    19,271.14
    -179.53 (-0.92%)
     
  • AIM

    741.00
    -4.29 (-0.58%)
     
  • GBP/EUR

    1.1677
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2453
    +0.0014 (+0.11%)
     
  • Bitcoin GBP

    52,022.03
    +2,625.49 (+5.32%)
     
  • CMC Crypto 200

    1,333.10
    +20.48 (+1.59%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.20
    +0.47 (+0.57%)
     
  • GOLD FUTURES

    2,398.30
    +0.30 (+0.01%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,681.86
    -155.54 (-0.87%)
     
  • CAC 40

    7,970.81
    -52.45 (-0.65%)
     

GSK hires three banks to advise on potential ViiV IPO -sources

LONDON, Feb 4 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) has hired Citi, Goldman Sachs (NYSE: GS-PB - news) and Morgan Stanley (Xetra: 885836 - news) as financial advisers on its ViiV Healthcare unit as the drugmaker explores a partial initial public offering (IPO) of its HIV medicines unit, sources familiar with the matter said.

Britain's biggest drugmaker, which is due to release full-years results at 1200 GMT, declined to comment on the news on Wednesday.

GSK first announced in October it was looking to float its fast-growing HIV drugs operation business as part of a plan to reshape its business, in what would be the drug industry's largest ever IPO.

The British group has a stake of nearly 80 percent in ViiV Healthcare, with Pfizer (NYSE: PFE - news) and Shionogi holding the rest.

The appointment of the three banks was first reported by Sky (LSE: SKY.L - news) News.

(Reporting by Ben Hirschler; Editing by Martinne Geller)